TITLE

Reducing the risk of overdose associated with propoxyphene

PUB. DATE
February 2010
SOURCE
Critical Care Nurse;Feb2010, Vol. 30 Issue 1, p9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the ways to reduce the risk of overdose that were associated with propoxyphene.
ACCESSION #
47784587

 

Related Articles

  • Dicycloverine/dextropropoxyphene/paracetamol abuse.  // Reactions Weekly;7/1/2013, Issue 1459, p18 

    The article presents a case study of a 30-year-old woman who experienced fatal dextropropoxyphene poisoing after consuming dicycloverine, dextropropoxyphene, and paracetamol.

  • Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market. Corcoran, Paul; Reulbach, Udo; Keeley, Helen S.; Perry, Ivan J.; Hawton, Keith; Arensman, Ella // BMC Clinical Pharmacology;2010, Vol. 10, p6 

    Background: Distalgesic, the prescription-only analgesic compound of paracetamol (325 mg) and dextropropoxyphene (32.5 mg) known as co-proxamol in the UK, was withdrawn from the Irish market as of January 2006. This study aimed to evaluate the impact of the withdrawal of distalgesic in terms of...

  • Propoxyphene and Overdose Risk. Elliott, William T. // Primary Care Reports;Sep2009 Supplement, p2 

    The article reports that a new box warning is being ordered by the Food and Drug Administration (FDA) in the U.S. for pain mediations, such as Darvon® and Darvocet®, containing propoxyphene. The FDA found that there are data connecting death an overdose of propoxyphene. On the other hand,...

  • Propoxyphene and Overdose Risk. Elliott, William T. // Clinical Oncology Alert;Sep2009 Supplement, p2 

    The article reports that a new box warning for propoxyphene-containing pain medications such as Darvon® and Darvocet® has been ordered by the Food and Drug Administration (FDA) in the U.S. The agency required such warning because of potential overdose. On the other hand, the request by...

  • Tamoxifen, SSRIs, and Breast Cancer Recurrence. Elliott, William T. // Internal Medicine Alert;9/16/2009 Clinical Briefs, p1 

    The article offers news briefs related to pharmacology in the U.S. The prasugrel, an oral antiplatelet agent use in preventing thrombosis in patients with acute coronary syndrome, has been approved by the Food and Drug Administration (FDA). The FDA is focusing its attention on the...

  • FDA Acts on Painkiller Risk.  // Chain Drug Review;7/20/2009, Vol. 31 Issue 12, p119 

    The article reports on the move of U.S. Food and Drug Administration (FDA) to reduce the risk of overdose in patients are taking pain medications that have propoxyphene. The FDA has ordered drug manufacturers to strengthen the label of products that contain propoxyphene including the boxed...

  • Propoxyphene: recommendation against use.  // WHO Drug Information;2010, Vol. 24 Issue 4, p306 

    The article reports on a 2010 decision which the U.S. Food and Drug Administration made to recommend against the continued prescribing and use of the pain reliever propoxyphene because data showed that the drug can cause serious toxicity to the heart.

  • Dextropropoxyphene: withdrawal.  // WHO Drug Information;2010, Vol. 24 Issue 3, p215 

    The article discusses notices which several government agencies gave to health care professionals in New Zealand to remind them that the consent to distribute dextropropoxyphene containing medicines was revoked on August 1, 2010 and that it will no longer be legal to sell, distribute or...

  • Dextropropoxyphene-containing analgesics cancelled.  // WHO Drug Information;Jan2012, Vol. 26 Issue 1, p34 

    No abstract available.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics